CQUEST responds to the FDA's draft guidance on core PROs in cancer trials

The CQUEST team, along with Jessica Roydhouse¹ of the Menzies Institute for Medical Research, University of Tasmania, recently wrote an editorial in response to implementing the FDA's 2021 draft guidance on core patient-reported outcomes (PROs) in cancer trials. This was published in ISOQOL's QualityTALK newsletter in August 2023. 

Read here: Implementing the FDA's draft guidance on core PROs in cancer trials: the challenge or a modular approach.

¹ ISOQOL representative on the CQUEST Steering Committee